- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07942363
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours (LET-PT)
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study
The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.
Secondary objectives are:
- To gain further insight into the feasibility of an LET-based treatment planning method in primary brain tumours.
- To assess additional side effects after PT for primary brain tumours.
- To investigate the response of primary brain tumours after PT.
Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Lieselotte Lauwens, MD
- Telefoonnummer: +32 16 34 76 00
- E-mail: lieselotte.lauwens@uzleuven.be
Studie Contact Back-up
- Naam: Maarten Lambrecht, MD PhD
- Telefoonnummer: +32 16 34 76 00
- E-mail: maarten.lambrecht@uzleuven.be
Studie Locaties
-
-
-
Leuven, België
- UZ Leuven
-
Contact:
- Maarten Lambrecht, MD PhD
- Telefoonnummer: +32 16 34 76 00
- E-mail: maarten.lambrecht@uzleuven.be
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients diagnosed with primary brain tumours including, but not limited to:
- Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted
- Ependymal tumours
- Tumours of the sellar region including, but not limited to, craniopharyngioma
- Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours
- Meningioma
- Primary neuroectodermal tumours
- Germ cell tumours
- Choroid plexus tumours
- Pineal tumours
-
Both adults and children are eligible for inclusion
-
Referred to PARTICLE for proton therapy treatment
-
Treatment with PT approved and reimbursed by RIZIV/INAMI
-
Ability of patient and/or parents or legal guardian to sign informed consent
Exclusion Criteria:
- Mixed photon-proton planning
- Re-irradiation
- Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: LET-based evaluation in treatment planning
|
Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.
Andere namen:
MRI assessments according to routine follow-up for TRIA and response assessment. Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module. Evaluating the incidence of CNS toxicities using the CTCAE v5.0 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
Tijdsspanne: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0. |
Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment planning feasibility: number of plan iterations.
Tijdsspanne: Baseline (during treatment planning).
|
Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: number of plans requiring LET-based replanning.
Tijdsspanne: Baseline (during treatment planning).
|
Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: planning effort
Tijdsspanne: Baseline (once before and once after LET-based replanning).
|
Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome). |
Baseline (once before and once after LET-based replanning).
|
|
CNS toxicities
Tijdsspanne: Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome. |
Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Tijdsspanne: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Tijdsspanne: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged >25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Tijdsspanne: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life. |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Response assessment
Tijdsspanne: At 6 and 12 months after proton therapy.
|
Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria. |
At 6 and 12 months after proton therapy.
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Tijdsspanne: Baseline (after treatment planning).
|
Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Tijdsspanne: Baseline (after treatment planning).
|
Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Tijdsspanne: Baseline (after treatment planning).
|
Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Tijdsspanne: Baseline (after treatment planning).
|
Comparing target coverage, reported as [CTV D98%] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neoplasmata per site
- Neoplasmata
- Neoplasmata van het zenuwstelsel
- Neoplasmata van het centrale zenuwstelsel
- Hersenneoplasmata
- Therapeutica
- Volksgezondheid
- Milieu en volksgezondheid
- Gezondheidstoestand
- Demografie
- Epidemiologische metingen
- Zware ionen radiotherapie
- Radiotherapie
- Kwaliteit van leven
- Protontherapie
Andere studie-ID-nummers
- S71405
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .